ESC 365 - Effect of Dapagliflozin on health-related quality of life in patients with heart failure: a meta-analysis of Randomized Controlled Trials

ESC Professional Premium Access

Effect of Dapagliflozin on health-related quality of life in patients with heart failure: a meta-analysis of Randomized Controlled Trials

Session: Understanding the effects and utilisation of SGLT2 inhibitors in heart failure

Topic: Pharmacotherapy

Speaker: Mrs M. De Souza (Curitiba, BR)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Mrs Mariana De Souza

Federal University of Parana, Curitiba (Brazil)

0 follower

5 more presentations in this session

Disparities in SGLT2i utilization among heart failure patients with different ejection fraction in China: findings from chinese cardiovascular association database-heart failure center registry

Speaker: Mr Q. Zhang (Beijing, CN)

Real-life data on the tolerability of SGLT2 inhibitors in elderly patients with heart failure

Speaker: Mr A. Hacil (Paris, FR) Professor O. Hanon (Paris, FR)

The safety of in-hospital initiation of SGLT2 inhibitor with MRA therapy in patients hospitalized for heart failure with a reduced left ventricular ejection fraction and chronic kidney disease

Speaker: Mrs O. Obertynska (Vinnitsa, UA)

Impact of dapagliflozin on supraventricular and ventricular arrhythmias, assessed by Holter ECG, in patients with heart failure with reduced ejection fraction

Speaker: Professor A. Abdellah (Ismailia, EG)

Beneficial effects of the SGLT2 inhibition on oxidative skeletal muscle in infarcted rats

Speaker: Miss L. Souza (Botucatu, BR)

Access the full session

Understanding the effects and utilisation of SGLT2 inhibitors in heart failure

Speakers: Mrs M. De Souza, Mr Q. Zhang, Mr A. Hacil, Professor O. Hanon, Mrs O. Obertynska...

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources